29 results about "Synaptic function" patented technology

The application discloses a water-soluble polymer-based proton-type memristor and a preparation method thereof. The memristor has a sandwich structure and is sequentially composed of a top electrode, an inorganic resistive switching functional layer, an organic resistive switching functional layer and a bottom electrode. The top electrode is a metal active electrode, the bottom electrode is indium tin oxide (ITO), the inorganic resistive switching functional layer is a metal oxide film, and the organic resistive switching functional layer is a doping system composed of a water-soluble polymer and a doping material. The preparation process of the proton-type memristor is reliable and stable. The obtained memristor has the characteristics of high biocompatibility and green environmental protection. The device performance consistency and environmental dependence are improved, and the simulation of bionic synaptic plasticity is greatly improved. The device can be controlled by using a low voltage, has low power consumption, and has a good bidirectional current modulation effect, so that the device provides a possibility for further enriching synaptic functions and designing flexible wearable devices.

The invention provides a bipolar switchable piezoelectric ion mechanical receptor with a built-in synapse function and a preparation method of the bipolar switchable piezoelectric ion mechanical receptor. The thermal response is realized based on the phase separation behavior of the polymer network and the ionic liquid. Another purpose of the invention is to provide a piezoelectric signal polarity regulation and control method based on a phase separation mechanism, i.e., conversion from a positive piezoelectric signal to a negative piezoelectric signal. The invention provides an ionic gel material with thermal response, which has a uniform cross-linked polymer network structure and takes hydrophobic ionic liquid as a dispersion medium. The polymer network is formed by polymerizing and cross-linking acrylate monomers, and the ionic liquid is composed of imidazole cations and fluorine-containing anions.

The application discloses a dual-mode event trigger circuit based on light detection and optical synapse, comprising a detection module and a detection module; the detection module is used for triggering based on light events or voltage events, converting received optical signals or electrical signals into current signals, and transmitting the current signals to the detection module; the detection module is used for collecting current signals and performing corresponding event detection; wherein the detection module is configured with an optoelectronic device integrating light detection and optical synapse functions, when the optoelectronic device is subjected to light and no external voltage is applied, the optoelectronic device behaves as a light detection mode, at the same time, the detection module works in a light event detection mode; when the optoelectronic device is simultaneously subjected to an external voltage and light, the optoelectronic device behaves as an optical synapse mode, at the same time, the detection module works in a voltage event detection mode. The circuit realizes dual-mode event triggering by using simple devices, has compact circuit structure, high device integration, does not need a complex multi-stage decision circuit, and effectively reduces energy consumption.

This disclosure provides methods for treating neurodegenerative diseases and restoring neuronal synaptic function by administering adenosine-to-inosine editing modifiers.

The invention discloses a novel brain protein enzymolysis active peptide for improving concentration and application thereof. Belongs to the technical field of new active peptide preparation. According to the invention, fresh pig brain is used as a raw material for enzymolysis and purification to successfully prepare the novel active peptide PAVP through brain protein enzymolysis. Efficacy verification is further carried out on the oligopeptide PAVP, and experimental results show that the oligopeptide PAVP can remarkably prolong the time of exploration of mice on new things in a new things recognition experiment and improve the concentration degree; in order to further verify the action mechanism of the PAVP, the expression quantities of synaptic plasticity markers PSD-95, BDNF and p-CREB in a mouse body are detected on the molecular level, and experimental results show that the PAVP not only repairs the synaptic touchable injury, but also possibly further enhances the synaptic function so as to achieve the purpose of improving the concentration degree.

The invention provides a photoelectron synaptic device based on a Z-type heterojunction and a preparation method and application thereof.The photoelectron synaptic device sequentially comprises a top electrode layer, a Z-type heterojunction functional layer and a bottom electrode layer from top to bottom, and the Z-type heterojunction functional layer is formed by tightly contacting a first semiconductor material layer and a second semiconductor material layer; and energy bands of the first semiconductor material layer and the second semiconductor material layer are staggered to form a Z-shaped energy band. The photoelectron synaptic device is simple in structure, the Z-type heterojunction functional layer is designed, and a plurality of synaptic behaviors are simulated by using a unique carrier recombination mechanism of the Z-type heterojunction, so that bidirectional synaptic function simulation of inhibition / excitation under the same photostimulation can be realized only through voltage switching, and the photoelectron synaptic device is applicable to various synaptic functions. And a core thought is provided for the design of a multifunctional integrated photoelectron synaptic device.

The application discloses an induction method for directional differentiation of neural stem cells into dopaminergic neurons, comprising the following steps: S1, activation and adhesion of NSCs; S2, directional induction of midbrain precursor cells; S3, directional induction of dopaminergic neurons; and S4, synaptic function maturation induction. The induction method for directional differentiation of neural stem cells into dopaminergic neurons can significantly improve the directional efficiency and lineage specificity of the midbrain precursor cells: by adding salvianolic acid B and icariin, and in cooperation with SHH, FGF8 and other induction factors, the midbrain lineage-specific signal pathway can be efficiently activated, the positive rate of the midbrain precursor cell marker LMX1A is increased to more than 76%, which is far better than 49% of the existing system, and abnormal differentiation of non-midbrain lineages is effectively inhibited.

The invention discloses application of a molecular target Ptchd1 in nerve synaptic function and consciousness regulation and related diseases. Whole genome screening finds that Ptchd1 is a key molecular target for consciousness regulation, and animal experiments prove that the target has an important regulation effect on neuronal synaptic vesicle release and consciousness disappearance caused by general anesthesia drugs. In view of the fact that Ptchd1 can regulate and control drug-induced awareness disappearance and neuronal synaptic delivery, related treatment with Ptchd1 as a target spot has significant potential values in the following fields: i) application in preparation of reagents for regulating and controlling a neuronal synaptic function and awareness regulation and control; the invention also relates to application of the pharmaceutical composition in preparation of drugs for promoting awakening after anesthesia and application of the pharmaceutical composition in preparation of drugs for promoting awakening of diseases related to disturbance of consciousness, wherein the diseases related to the disturbance of consciousness comprise vegetative people, micro-consciousness or brain injury coma.

The invention relates to the technical field of artificial synapses, in particular to a composite artificial synapse which comprises a core functional layer, the core functional layer is a composite material layer, and the composite material layer is formed by mixing a SrAl2O4-based long afterglow material and a NaYF4-based up-conversion material; eu < 2 + > and Dy < 3 + > are doped in the SrAl2O4-based long afterglow material; yb < 3 + > and Tm < 3 + > are doped in the NaYF4-based up-conversion material; under excitation of near-infrared light, the NaYF4-based up-conversion material transmits energy to the SrAl2O4-based long-afterglow material through up-conversion luminescence, so that the SrAl2O4-based long-afterglow material generates long-afterglow luminescence, and a synaptic function is realized; through thermal stimulation, the release process of defect trap electrons in the SrAl2O4-based long afterglow material is regulated and controlled, and thermally induced synaptic plasticity is realized. According to the invention, SrAl2O4: Eu < 2 + >, Dy < 3 + > and NaYF4: Yb < 3 + >, Tm < 3 + > are coupled, so that long afterglow luminescence (LPL) of near-infrared triggering and thermal regulation is realized, and information encryption, handwritten number recognition and mechanical arm gesture control are realized by artificial synapses based on photo-thermal synergistic stimulation.

The invention provides application of a related preparation of a targeted synaptic receptor in preparation of a medicine for treating intellectual disturbance, and belongs to the technical field of medicines. The invention aims at intellectual disturbance related to synaptic activity disorder, aims at excitatory or inhibitory receptors, recovers synaptic steady state and intervenes in treatment of cognitive decline. Aiming at the abnormal activation of the AMPA type glutamate receptor, the perampanel can be orally taken to recover the excitatory synaptic function and neural circuit activity balance in the brain and the cognitive levels of learning, memory and the like; aiming at abnormal inhibition of GABAA type receptors, muscarinic alcohol can be injected in the intraperitoneal cavity, and the inhibitory synaptic function and neural circuit activity level in the brain as well as cognitive levels such as learning and memory can be recovered.

The embodiment of the invention discloses a light-operated artificial synaptic device and a preparation method thereof. The artificial synaptic device comprises a substrate, a light-emitting layer and a synaptic function layer which are sequentially stacked in the thickness direction: the light-emitting layer is arranged on the substrate, and the light-emitting surface of the light-emitting layer faces the synaptic function layer; and the synaptic function layer is used for responding to the light signal emitted by the light-emitting layer and generating a conductivity change for simulating a biological synaptic behavior. According to the light-operated artificial synapse device provided by the invention, the light-emitting layer is integrated into the artificial synapse device, so that light signals do not need to be propagated for a long distance and can directly act on the synapse function layer in a directional manner, and the problem of low light coupling efficiency of the existing light-operated synapse is further solved.

The invention relates to the technical field of Gaucher disease treatment, in particular to application of nicotine in preparation of drugs for relieving, adjuvant therapy or treatment of Gaucher diseases. The invention reveals for the first time that nicotine can enhance mitochondrial autophagy mediated by a PGC1 alpha / Parkin pathway by reducing accumulation of glucosylceramide and up-regulating protein expression of PGC1 alpha and Synaptophysin in a hippocampal region, also improves synaptic function and various neurotransmitter levels, enhances learning memory and application ability, and further improves neurodegenerative diseases caused by Gaucher disease.

The invention relates to the technical field of biological medicine, in particular to a medicine for targeting cathepsin B and application of the medicine in autism treatment. The medicine is prepared into an oral or injection preparation by synthesizing a small-molecule inhibitor with high selectivity and combining with pharmaceutic adjuvants, so that the activity of cathepsin B can be effectively inhibited, neuroinflammation can be relieved, and synaptic function balance can be recovered. Experiments show that the medicine remarkably improves social behavior defects and repetitive behaviors of BTBR T + Itpr3tf / J mice, and meanwhile, the activity of cathepsin B and the level of inflammatory factors in brain tissue are reduced. The dosage of the composition is 0.1-10 milligrams per kilogram of body weight, the administration route comprises oral administration or injection, and the storage condition is that the composition is stored in a dark place at the temperature of 2-8 DEG C. The invention provides a clear action mechanism and a remarkable treatment effect.

This invention provides the application of a nutritional composition in the preparation of products that promote neural development and support the improvement of neural function. The research of this invention found that intervention in the body using a nutritional composition comprising *Bifidobacterium animalis* subsp. *lactobacterium* CP-9 and 3'-sialic acid lactose can promote the development of amygdala neuronal structure, improve neural plasticity, and enhance synaptic function, thereby promoting the formation and functional maturation of the normal amygdala structure. As a core brain region regulating emotional responses, social cognition, and stress responses, the normal development of the amygdala plays a crucial role in an individual's emotional regulation ability, social interaction behavior, cognitive function, and mental health. Therefore, this invention promotes the structural and functional development of the amygdala through nutritional intervention, ultimately improving an individual's emotional regulation ability, social interaction behavior, cognitive function, and mental health.

The invention relates to an artificial synaptic device based on chiral perovskite and a preparation method thereof. The device sequentially comprises a substrate, a comb-shaped bottom electrode, a chiral perovskite functional layer and a comb-shaped top electrode from bottom to top, wherein the projection direction of the bottom electrode comb teeth and the projection direction of the top electrode comb teeth are crossed at an angle of 90 degrees; the chemical general formula of the chiral perovskite functional layer is A < 1-x > A'x PbX3, A is a chiral organic cation, A 'is an achiral organic cation, and X is one or more of Cl <->, Br <-> and I. The device obtained by the invention can respond to a chiral optical signal and complete processing and storage of chiral information, and has an excellent brain synaptic-like function at the same time.

The invention discloses a novel active peptide composition for improving concentration and application thereof. Belongs to the technical field of novel active peptides. In the brain peptide research process, various new active peptides are extracted and prepared by taking pig brain as a raw material, and the research on related functions finds that the new active peptide PAVP has the effect of improving concentration; in addition, when the new active peptide PAVP and the VVAVPGN obtained through separation are mixed according to the mass ratio of 1: 1-1: 5, compared with the condition that the new active peptide PAVP and the VVAVPGN act independently, the exploration time of CUMS model mice on new things can be remarkably prolonged, and a synergistic interaction effect is achieved; when the two components cooperate with each other, the two components also have a synergistic effect on improving the expression quantity of PSD-95 and BDNF, which indicates that when the two components are combined, the capability of repairing synaptic plasticity injury of mice due to model construction can be remarkably improved, and the synaptic function is enhanced, which is a core molecular mechanism for improving concentration.

This invention discloses a method for constructing an animal model of frontotemporal lobe degeneration using TAF15 pre-fabricated precursor fibers, belonging to the field of biotechnology. The TAF15PFFs of this invention are formed by the aggregation of protein fragments with the amino acid sequence shown in SEQ ID NO.1. They can promote the aggregation of TAF15 protein in the brain, induce neuronal damage and synaptic dysfunction, leading to cognitive impairment and anxiety and depression-like behaviors in mice. Injecting TAF15PFFs into the prefrontal cortex of mice can construct a mouse model of frontotemporal lobe degeneration. This invention provides a new animal model for studying the pathogenesis of frontotemporal lobe degeneration and screening therapeutic drugs.

The invention provides an application of ancient-Chinese health-preserving essence in preparation of a nerve repairing medicine, and belongs to the technical field of biological medicines. The invention provides an application of ancient-Chinese health-preserving essence in preparation of a nerve repairing medicine. The ancient-Chinese health-preserving essence can improve the plasticity of nerve synapses and improve the communication capability of neurons by promoting the repair of a dendritic structure and enhancing the synaptic function. And secondly, the ancient-Chinese health-preserving essence can further improve the function of VGLUT1 and the stability of MAP2 by regulating NCAM2, so that the health of nerve synapses is promoted, and nerve repair is realized.

The invention discloses a medicine for treating neurodevelopment disorder diseases. The invention provides a etiological treatment method capable of crossing a blood brain barrier and directly targeting neural synaptic function repair, stable expression of an exogenous TBL1XR1 gene in a plurality of key brain regions (including hippocampus, prefrontal lobe, basal ganglion and the like) can be realized, and the TBL1XR1 gene has good brain targeting property and tissue affinity, and can be applied to the field of brain diagnosis and treatment. The synaptic disorder in the nervous system and the related nerve development process can be improved, and the composition has good safety in the aspects of system and nerve immunity. The application opens up a new intervention path for the neurodevelopment disorder diseases, especially the neurodevelopment disorder diseases caused by TBL1XR1 gene mutation.

Provided are methods of treating neuropsychiatric disorders including obsessive-compulsive related disorders, tic disorders, glutamate excitotoxicity related disorders, autism spectrum disorders, and other medical conditions in patients with a mutation in genes involving function, structure, or plasticity, including but not limited to SHANK3, SAPAP3, NLGN3, NLGN4, NRXN1, CNTNAP2, or MECP2. The methods include administering an effective amount of a histamine type 1 receptor agonist and / or histamine type 3 receptor antagonist or inverse agonist, their pharmaceutically acceptable salts, analogs, metabolites, and prodrugs, including prodrugs of its metabolites, to patients in need of such treatment.

Provided herein are apparatuses, systems and methods for non-invasively assessing synaptic dysfunction in a patient with Alzheimer's Disease. Transcranial magnetic stimulation (TMS) is applied to at least one brain region of the patient. A plurality of TMS evoked potentials generated in response to the TMS applied to the at least one brain region of the patient is recorded with a plurality of electroencephalography (EEG) electrodes. At least one characteristic of the plurality of TMS evoked potentials is analyzed to assess synaptic dysfunction in the patient. An indication of the synaptic dysfunction assessment of the patient is output.

The invention discloses a photo-erasable double-capture center photosynaptic material CaSb2O6: Ti as well as a preparation method and application of the photo-erasable double-capture center photosynaptic material CaSb2O6: Ti. The material is charged under excitation of 275 nm light, carriers are stored in a capture center, the stored carriers are erased under excitation of 365 nm light, and thermoluminescence returns to zero after erasing; the capture center comprises a shallow energy level capture center and a deep energy level capture center; the shallow energy level capture center is used for realizing a common short-term photosynaptic function, and the deep energy level capture center is used for realizing a long-term memory function; the dipulse facilitation index in the synaptic behavior is greater than or equal to 172%, and the facilitation curve is S-shaped and can be used for an activation function in a neural network. The photosynapse response signal is regulated and coded by various parameters such as pulse intensity, pulse number, pulse time, pulse frequency, duty ratio, pulse light wavelength and the like of the excitation light pulse. The thick film technology of the material is compatible with polydimethylsiloxane, the material can be used for duty ratio coding handwritten anti-counterfeiting and reconfigurable reservoir calculation, vegetable-fruit double-task end side identification is achieved, and the accuracy rate is gt; 90%. The material is simple in composition, convenient to prepare, flexible and suitable for artificial intelligence edge equipment.

The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of indole-3-propionic acid in preparation of medicines for improving neuroinflammation caused by ionizing radiation. Research results show that indole-3-propionic acid can inhibit oxidative stress and neuroinflammation, recover the synaptic function of hippocampus nerves and improve intestinal barrier by regulating and controlling a microglial cell Wn1 / STAT3 pathway, and prompt that IPA may become a potential therapeutic drug for irradiation-induced brain function impairment.

The application discloses a composition for treating intellectual disability, application thereof and a drug screening method. The application verifies the effectiveness of the composition in improving the expression level of CAPZA2, restoring synaptic function and improving neural behavior by introducing an AAV virus carrying an hCAPZA2 gene into a CAPZA2 hybrid knockout or mutant mouse model. The application not only provides new hope for the treatment of intellectual disability related to the CAPZA2 gene, but also opens up a new direction for the application of gene therapy in neurodevelopmental diseases.

The invention provides engineered mesenchymal stromal cells (ePSCs) with a phagocytosis function and an application of the engineered mesenchymal stromal cells (ePSCs) in treatment of Alzheimer's disease (AD). The engineered mesenchymal stromal cells (ePSCs) are obtained by inducing fibroblasts to be reprogrammed by adopting a chemical small molecule combination. The invention discloses a set of genetic modification-free reprogramming scheme based on a chemical small molecule composition, which is used for efficiently converting fibroblasts from somatic cells into ePSCs (enhanced pluripotent stem cells) by sequentially activating an endogenous reprogramming pathway. The obtained ePSCs highly express phagocytic function related proteins (including TMEM119, SCARB1, APOE, CTSD and the like), and the ability of removing beta amyloid protein (A beta) plaques is significantly enhanced. In-vitro and in-vivo AD model verification proves that transplanted ePSCs can be directionally migrated to an intracerebral lesion area, and through a synergistic effect mechanism: (i) directly phagocytizing and degrading A beta aggregates, and (ii) providing neuroprotective factors (such as HTRA1, GLUL, SLIT1, TUBB3 and NPTX2) to inhibit neuroinflammatory response, promote nerve regeneration, effectively improve the neuron survival state and synaptic function integrity, and improve the neurological activity of the brain. And finally, cognitive function recovery is promoted.

The invention belongs to the technical field of neuromorphic devices, and particularly relates to a PN junction memristive synapse device for aging-induced nanocrystalline grain boundary fusion and a preparation method of the PN junction memristive synapse device. A NiOx / SnO2 quantum dot heterojunction is prepared through a low-temperature solution method, a stable PN junction is formed by utilizing nanocrystalline interface atom reconstruction in the aging process, and the memristive synapse device of an ITO / NiOx / SnO2 / Ag structure is constructed. According to the device, interface atom diffusion is accelerated through aging or heat treatment at 80 DEG C for 12 hours, PN junction optimization is achieved, and the device has excellent biological synaptic function simulation capacity including long-term gain / inhibition effect, excitation / inhibition of post-synaptic current and the like. According to the method, the interface fusion of the nanocrystalline is regulated and controlled through aging, the limitation of a traditional high-temperature process is broken through, low-power-consumption and low-cost preparation is realized, and a novel device scheme is provided for brain-like calculation.

This invention provides a ferroelectric memristor based on aluminum scandium nitride, its fabrication method, and its applications. The memristor structure provided by this invention can be represented as Pd / Al. 0.77 Sc 0.23 N / TiN / Si. The fabrication method of this memristor includes: growing a TiN bottom electrode on a Si substrate, and growing Al on the TiN bottom electrode by nitrogen reactive magnetron sputtering. 0.77 Sc 0.23 N functional layer; in Al 0.77 Sc 0.23 A palladium electrode layer is grown on the N-functional layer. This invention is the first to use aluminum scandium nitride as the intermediate functional layer of a non-volatile memory. It has strong self-rectification characteristics and can better solve problems such as crosstalk when applied to cross-arrays. It can develop and realize new biological synaptic functions in simulated synaptic neuron systems, and its performance is good. It is a non-volatile memory with good storage performance, low turn-on voltage, and broad application prospects that simulates biological synaptic behavior.

Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta-associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.

The invention discloses a composition for treating dysgnosia and application thereof. According to the invention, the AAV virus carrying the hCAPZA2 gene is introduced into a CAPZA2 heterozygous knockout or mutated mouse model, and the effectiveness of the AAV virus in the aspects of improving the CAPZA2 expression level, recovering the synaptic function and improving the neural behavior is verified. The invention not only provides a new hope for treating the mental disorder related to the CAPZA2 gene, but also opens up a new direction for the application of gene therapy in neurodevelopment diseases.